You are here

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018

HOUSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the year ended December 31, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments.
Thursday, February 21, 2019 - 16:59